Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + XELOX + Bevacizumab for CRLM
NCT04940546Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Started Jun 2021; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04940546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940546.